Skip to main content
IBOCInternational Bancshares CorporSell5.3·$77.10
IBOC · Decision

Should you buy International Bancshares Corpor (IBOC)?

Updated

Operating margins of 50% and a Piotroski financial-health score of 8 out of 9 make this a high-quality regional bank, but the stock has effectively reached its near-term price target with an unfavorable risk/reward ratio of 0.16-to-1, leaving little margin of safety for new buyers.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
5.3/10
Price
$77.10
Entry / Take Profit (TP) / Stop Loss (SL)
/ $75.80 / $74.25

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

The stock sits just below its near-term resistance target with only 0.6% remaining headroom and a risk/reward ratio of 0.16-to-1, meaning the potential downside materially outweighs any incremental gain from current levels.

Stable
Price targets
Expectation
A meaningful pullback from resistance to a level where the upside-to-target exceeds 8% and the risk/reward ratio exceeds 1.5-to-1, restoring an asymmetric entry setup.

CounterPrice momentum is strongly positive — above all moving averages with a golden cross formation — suggesting the stock may push through resistance and reprice higher, which would invalidate the unfavorable geometry.

Net margins of 50% and a Piotroski financial-health score of 8 out of 9 place this bank among the best-in-class margin franchises in its peer group, providing a durable quality foundation.

Stable
Quality breakdown
Expectation
Reported net margin remains above 45% in each of the next two quarterly filings, preserving the margin advantage over peers.

CounterStrong margins without a competitive moat — as the data explicitly notes — can erode if the rate environment shifts or lower-cost competitors take market share; there is no structural barrier identified to defend the current margin level.

Three of the last four quarters beat consensus estimates, though the two older beats were by very large margins in a different period, and the most recent quarter delivered a miss of -2.4%, interrupting the recent beat pattern.

Stable
Earnings
Expectation
The next two quarterly reports return to positive earnings surprises, re-establishing the beat pattern after the most recent shortfall.

CounterWith guidance unknown and the most recent result a miss, the historical beat average is heavily influenced by older data points; forward consistency cannot be assumed from the historical record alone.

▸ Show 1 more pillar

A golden cross formation with price above all major moving averages and rising on-balance volume confirms that near-term buying pressure is dominant, supporting the current trading range.

Stable
Momentum breakdown
Expectation
Price sustains above the 200-day moving average for the next three months, confirming that the momentum signal is durable rather than a short-lived technical bounce.

CounterThe stock is already near its 52-week high, leaving diminishing room for further near-term appreciation before a natural consolidation period that could retrace a portion of recent gains.

→ Full pillar scorecard with all 4 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Net margins of 50% and a Piotroski financial-health score of 8 out of 9 place this bank among the best-in-class margin franchises in its peer group, providing a durable quality foundation.

    Trip ifReported net margin falls below 40% for 2 consecutive quarters.

  • P2The stock sits just below its near-term resistance target with only 0.6% remaining headroom and a risk/reward ratio of 0.16-to-1, meaning the potential downside materially outweighs any incremental gain from current levels.

    Trip ifPrice breaks above $83 and sustains for 5 consecutive trading days, demonstrating that resistance at $75.57 was cleared and more upside existed.

  • P3Three of the last four quarters beat consensus estimates, though the two older beats were by very large margins in a different period, and the most recent quarter delivered a miss of -2.4%, interrupting the recent beat pattern.

    Trip ifEPS surprise falls below 0% for 2 consecutive quarters.

  • P4A golden cross formation with price above all major moving averages and rising on-balance volume confirms that near-term buying pressure is dominant, supporting the current trading range.

    Trip ifPrice falls below the 200-day moving average and sustains below it for 20 consecutive trading days.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for International Bancshares Corpor (IBOC) is SELL_IF_HOLDING with medium conviction, score 5.3/10 at $77.10. The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -0.48 is supplementary context, not the trigger.

2. What would change the verdict

The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.8>=5.5.

3. What the engine sees

On the bull side: Strong earnings beat streak (3/4). On the bear side: Analyst target reached - limited upside remaining; Near 52-week high (-0.0% away); Weak growth. Active engine warnings: V8: Target reached (-4.1% upside), V9 Gate Failed: ASYMMETRY:-0.5=NEGATIVE.

4. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $77.10, with structural invalidation at $74.25. The asymmetric R:R against a reversal hypothesis is -0.46 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates IBOC — 10-dimension breakdown →

Bull case

  • Strong earnings beat streak (3/4)

Bear case

  • Analyst target reached - limited upside remaining
  • Near 52-week high (-0.0% away)
  • Weak growth
Home Stocks IBOC Buy or sell?